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We read with great interest the article by Kalokhe et al.,1 in
which the authors presented a case of cardiac device-related
Aspergillus endocarditis in a patient with a pacemaker and also
made an effort to collect and review the related cases in the
literature. We would like to share our case of endomyocardial
invasive aspergillosis, which was not cited in their review.2
Although it is well known that exposure to Aspergillus
organisms/spores is common, the disease caused by tissue
invasion with these fungi is, however, uncommon and occurs
primarily in the setting of immunosuppression. In 2005 we
reported a case of rapidly advancing invasive endomyocardial
aspergillosis secondary to prolonged usage of multiple broad-
spectrum antibiotics in a non-immunocompromised host.2 A 36-
year-old cotton textile worker presented to our institution with a
3-month history of weight loss and fatigue. He reported the
prolonged use of multiple broad-spectrum antibiotic treatment. An
echocardiogram demonstrated multiple endomyocardial vegeta-
tions and a mass in the left atrium. A myocardial biopsy specimen
revealed an invasive endomyocardial aspergillosis. Treatment was
started with amphotericin B and heparin for a presumed left atrial
thrombus. The patient died because of a rupture of the mycotic
aneurysm that resulted in a cerebral hemorrhage.
This case illustrates the risk of an invasive fungal infection in a
non-immunocompromised host who has been exposed to pro-
longed use of antibiotics in the setting of environmental exposure
to opportunistic invasive fungal infections. We also underline the
need to avoid the use of heparin in this setting due to the risk of
cerebral hemorrhage with the possible existence of a mycotic
aneurysm, which might lead to fatal outcome. We would also like1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.05.014to criticize the term ‘endocarditis’ in the setting of cardiac
aspergillosis. In fact, the infection is not solely localized in the
endocardium, which we demonstrated nicely on biopsy.2 Since the
behavior of aspergillosis is invasive, in our view the most suitable
term is ‘endomyocardial aspergillosis’ instead of ‘endocardial
aspergillosis’.
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